MedTrace Logo

Predicting Ultrasound-Guided Thoracic PVB Success in Herpetic Neuralgia

NCT06761924 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2025-01-07

No results posted yet for this study

Summary

This study aims to fill the knowledge gap by investigating the predictors of success for TPVB in patients with herpetic neuralgia. By identifying demographic, clinical, previous medications and procedural factors associated with positive outcomes, this research seeks to enhance the efficacy of TPVB and improve pain management strategies for patients suffering from herpetic neuralgia.

Conditions

  • Patient Satisfaction

Interventions

PROCEDURE

Ultrasound-Guided Thoracic Paravertebral nerve block

The patients will receive ultrasound-guided TPVB with 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone (10 mL volume)

PROCEDURE

Ultrasound-Guided Thoracic Paravertebral nerve block

ultrasound-guided TPVB with 10 mL of saline without knowing which treatment they are receiving, maintaining blinding throughout the study.

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Dina M Fakhry, MD · Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-28
Primary Completion
2025-09-30
Completion
2025-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06761924 on ClinicalTrials.gov